Teachers Retirement System of The State of Kentucky Purchases 8,640 Shares of Dermira Inc (DERM)

Teachers Retirement System of The State of Kentucky lifted its position in shares of Dermira Inc (NASDAQ:DERM) by 25.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 42,915 shares of the biopharmaceutical company’s stock after purchasing an additional 8,640 shares during the quarter. Teachers Retirement System of The State of Kentucky’s holdings in Dermira were worth $468,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Orbimed Advisors LLC acquired a new stake in shares of Dermira during the 2nd quarter worth approximately $9,491,000. Engineers Gate Manager LP acquired a new stake in shares of Dermira during the 2nd quarter worth approximately $940,000. Schwab Charles Investment Management Inc. grew its holdings in shares of Dermira by 9.5% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 172,002 shares of the biopharmaceutical company’s stock worth $1,583,000 after purchasing an additional 14,872 shares in the last quarter. grace capital bought a new position in shares of Dermira during the 2nd quarter worth approximately $153,000. Finally, First Midwest Bank Trust Division lifted its position in shares of Dermira by 3.0% during the 3rd quarter. First Midwest Bank Trust Division now owns 338,060 shares of the biopharmaceutical company’s stock worth $3,685,000 after buying an additional 9,890 shares during the period. 84.90% of the stock is currently owned by institutional investors.

Dermira stock opened at $10.89 on Friday. The company has a current ratio of 5.29, a quick ratio of 5.25 and a debt-to-equity ratio of 5.21. Dermira Inc has a one year low of $6.98 and a one year high of $31.42.

Dermira (NASDAQ:DERM) last issued its quarterly earnings data on Wednesday, November 7th. The biopharmaceutical company reported ($1.58) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.63) by $0.05. Dermira had a negative return on equity of 184.43% and a negative net margin of 496.49%. The firm had revenue of $0.72 million during the quarter, compared to the consensus estimate of $0.80 million. On average, equities analysts expect that Dermira Inc will post -5.2 EPS for the current year.

In other Dermira news, Director Matthew K. Fust sold 4,000 shares of Dermira stock in a transaction on Friday, October 19th. The stock was sold at an average price of $13.75, for a total value of $55,000.00. Following the completion of the transaction, the director now owns 14,051 shares in the company, valued at approximately $193,201.25. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 14.80% of the company’s stock.

Several equities analysts recently commented on the company. Cantor Fitzgerald restated a “buy” rating and set a $20.00 target price on shares of Dermira in a research report on Wednesday, September 5th. Zacks Investment Research upgraded Dermira from a “sell” rating to a “hold” rating in a research report on Wednesday, October 10th. BidaskClub upgraded Dermira from a “hold” rating to a “buy” rating in a research report on Friday, September 14th. Mizuho restated a “hold” rating and set a $10.00 target price on shares of Dermira in a research report on Tuesday, October 2nd. Finally, ValuEngine upgraded Dermira from a “sell” rating to a “hold” rating in a research report on Thursday, November 1st. Three equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Dermira presently has a consensus rating of “Buy” and a consensus target price of $21.43.

ILLEGAL ACTIVITY WARNING: “Teachers Retirement System of The State of Kentucky Purchases 8,640 Shares of Dermira Inc (DERM)” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/12/08/teachers-retirement-system-of-the-state-of-kentucky-purchases-8640-shares-of-dermira-inc-derm.html.

Dermira Company Profile

Dermira, Inc, a biopharmaceutical company, identifies, develops, and commercializes therapies to treat dermatologic diseases. The company's product candidates include Glycopyrronium tosylate, a novel form of an anticholinergic agent that has completed Phase III clinical trial for the treatment of primary axillary hyperhidrosis; Olumacostat glasaretil, a novel small molecule designed to target sebum production, which is in Phase III clinical trial for the treatment of acne vulgaris; and lebrikizumab, a novel humanized monoclonal antibody targeting interleukin 13 that is in Phase 2b development for the treatment of moderate-to-severe atopic dermatitis.

Read More: Market Capitalization

Want to see what other hedge funds are holding DERM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dermira Inc (NASDAQ:DERM).

Institutional Ownership by Quarter for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply